Cheap, easy, and almost never doing what it was sold doing. The one effect the trial literature actually supports — intercepting specific dietary toxins in your gut — is narrow enough that for most readers it is not the reason to buy. Skin, body odor, energy, blood oxygen, weight loss: marketing without controlled trials behind it. Eat your greens; the salad does what the salad does, and the drops mostly add green urine.
Chlorophyll is the green molecule plants use to capture sunlight — a flat, ringed structure with magnesium at its centre, anchored in chloroplast membranes by a long fatty tail. Chlorophyllin, the kind sold in liquid drops and capsules, is a modified version: the magnesium is swapped for copper and the fatty tail is cut off, which makes the molecule dissolve in water and survive your stomach. The two are different molecules with different behaviour, and the supplement aisle routinely treats them as interchangeable.
The interesting thing chlorophyllin does is structural. It is a flat ring shape, and it likes to stack against other flat ring shapes — including a specific class of dietary toxins called planar aromatic carcinogens. Aflatoxin (a mould toxin on poorly-stored peanuts and corn), heterocyclic amines from grilled and charred meat, and the carcinogens in smoke are all flat, all ringed, and all bind chlorophyllin in your gut. The pair is too big and too water-loving to cross from intestine into bloodstream, so the toxin gets excreted in stool instead of reaching your liver. Jubert et al. 2009 measured this directly in humans with a radiolabelled aflatoxin tracer and found roughly a third less reaching circulation when chlorophyllin was eaten alongside it.
This is the whole story, mechanistically. Chlorophyllin is an interceptor — it works in your gut at the moment the toxin is also in your gut. Taking it at bedtime to "cleanse" yesterday's barbecue does nothing; the meeting between molecule and toxin has to happen in the same meal. It cannot remove a toxin already absorbed, cannot pull anything out of stored tissue, and cannot reach anything outside the intestine.
What has actually been tested
The cornerstone trial — the reason chlorophyllin shows up in cancer-prevention literature at all — was run in Qidong, China, a region where, until recent improvements in grain storage, dietary aflatoxin exposure was extreme and liver cancer rates ran roughly fifty times those in the United States.
What that trial measured was a biomarker, not cancer deaths. No follow-up has carried the finding to a hard endpoint — hepatocellular carcinoma incidence, mortality — in Qidong or anywhere else. And it has not been repeated in a low-exposure population, where most adults' baseline aflatoxin is below detection anyway. The mechanism extends in animal data to grilled-meat carcinogens and to the chemicals in smoke, but a controlled human trial measuring those exposures with chlorophyllin co-administration has not been done.
For skin, two small pilot studies of a 0.1% topical chlorophyllin-copper cream applied twice daily in women with photodamaged faces and women with mild-to-moderate acne reported visible improvement after 8 to 12 weeks (Stephens et al. 2015; Sigler and Stephens 2015). Both had fewer than fifteen subjects, no placebo arm, and industry funding — the kind of signal that justifies a larger trial, not a confident recommendation. There has never been a controlled trial of oral chlorophyll for any skin endpoint, which is exactly the use the supplement aisle has been selling.
For the original "internal deodorant" claim — chlorophyllin for fecal and urinary odor, repeated in 1940s nursing-home and ostomy-care literature — the one controlled trial that was ever run found no difference from placebo (Christiansen and Pickrel 1964). The 1940s use was anecdotal; the modern claim inherits the anecdote without the controlled follow-up.
For wound healing, the same pattern. Chlorophyllin was a routine component of mid-century debriding ointments, on the strength of 1940s case series. The FDA's 2003 review of the over-the-counter skin-protectant market concluded that efficacy for wound healing had never been established (FDA 2003). Modern wound-care protocols do not include it.
What the videos got wrong
"It oxygenates your blood." Chlorophyll does resemble hemoglobin — both are porphyrins, both have a central metal atom — and the drink-it-to-make-your-blood-more-like-plant-blood claim leans on this. The resemblance ends at the picture. Chlorophyll has magnesium where hemoglobin has iron, has no oxygen-carrying ability, and is broken down by stomach acid and gut microbes long before any of it sees your bloodstream. Drinking it does not raise blood oxygen.
"It detoxes you." The carcinogen-binding effect is real but narrow — it works on flat ringed toxins, in your gut, at the moment they arrive. It does not "cleanse" the liver, pull toxins out of fat tissue, or reach anything that has already been absorbed. The detox frame takes an intestinal-interception mechanism and dresses it as a whole-body purge.
"It alkalizes your body." Your blood pH is held between 7.35 and 7.45 by buffering systems your body runs whether you cooperate or not. Diet does not move it. If diet moved it, you would be dead. "Alkalizing" is a marketing word.
"It clears your skin." Topical chlorophyllin-copper cream has a small-trial signal for acne and photodamage. The liquid drops you swallow — the form the recent viral cycle was promoting — have no controlled-trial support for any skin endpoint at all.
"It helps you lose weight." One small Swedish study reported reduced appetite from a chlorophyll-rich plant-membrane extract — not the drops you would buy at the supplement aisle. Replication has been thin and the effect small. This is not a weight-loss tool.
If you are going to take it
For the one well-evidenced use — intercepting dietary aflatoxin or charred-meat carcinogens — the protocol that comes out of the trial literature is straightforward.
For topical use on acne or photodamaged skin, the studied formulation is a 0.1% chlorophyllin-copper cream applied twice daily for at least 8 weeks. This is a different product class from the drink-it-in-water drops; do not assume swallowing the drops will do anything the cream might.
When to skip
Chlorophyllin sits among the safer things on the supplement shelf — it is an FDA-approved food colour, the acute safety profile is benign, and decades of use have not surfaced a serious signal. A few situations still call for caution.
Expected side effects are cosmetic: green stools, green urine, occasional mild stomach upset. A greenish skin tint has been reported at very high doses and reverses on stopping.
What it costs and what you are actually buying
Liquid drops run roughly $10 to $20 a month at supplement-aisle prices; capsules are similar; the topical chlorophyllin-copper cream is more like $30 to $60. Cheap by supplement standards, available everywhere, and broadly the same product from one brand to the next — the active ingredient is a defined chemical, not a proprietary blend.
The thing worth noticing: a cup of cooked spinach delivers roughly 70 milligrams of chlorophyll, and a normal day of greens gets you in the ballpark of the Qidong dose by mass — except as chlorophyll, not as the stabilized chlorophyllin form, and chlorophyll proper is more aggressively broken down by digestion. For general nutrition the salad is what the doctor ordered. For the specific carcinogen-interception use, the chlorophyllin in a capsule is what survives the trip. "Eat the greens" is real advice, and it is not a substitute for the drops on the one indication where the drops actually have a job.
Why most people who try it walk away disappointed
The modal experience: someone buys the drops on a clear-skin or detox promise, takes them for two weeks, sees green urine and nothing else they were hoping for, and concludes the dose was wrong or the brand was wrong. Neither is the actual problem. The product is doing exactly what its mechanism allows — binding flat ringed toxins in the gut — and the person isn't measuring that. The marketed outcome and the molecular reality were never connected to each other.
The second-most-common pattern: someone takes chlorophyllin away from food — first thing in the morning, before bed, mixed into water during the afternoon — because the bottle says "for daily wellness" and never says "with food". The mechanism gives up most of its effect that way. The toxin and the binder have to be in the same stomach at the same time, and "daily wellness" is not a stand-in for "with meals".
If you're interested in what's adjacent
For the carcinogen-interception angle: the broader chemoprevention literature on cruciferous vegetables (sulforaphane, isothiocyanates) covers a different family of compounds doing related work at the liver and the gut. For evidence-based skin interventions: topical retinoids, sunscreen, and benzoyl peroxide cover most of what chlorophyllin-copper cream is reaching for, with much larger trial bases. If aflatoxin is the worry, where your peanuts come from and how they are stored does more than supplementation can.
Substance and claimed effects
Chlorophyll is the green pigment in every photosynthetic plant — a magnesium-centered porphyrin (more specifically a chlorin) with a long phytol tail anchoring it in chloroplast membranes. Chlorophyllin, sold as drops, capsules, and topical formulations, is a semi-synthetic derivative: the magnesium is substituted with copper and the phytol tail is saponified, making the molecule water-soluble. The two are routinely conflated in marketing but are not the same molecule and do not have identical pharmacology — chlorophyll proper is largely fat-soluble and substantially degraded by gastric digestion, whereas chlorophyllin survives the gut and is partially absorbed (Yang et al. 2014).
Marketed claims are wide. The strongest is intestinal binding of dietary planar-aromatic carcinogens — aflatoxin B1, heterocyclic amines, polycyclic aromatic hydrocarbons. The middle-strength claims are mild topical effects on photoaged and acne-prone skin from chlorophyllin-copper complex creams, and "internal deodorant" use for colostomy and incontinence patients dating to the 1940s. The weakest claims — viral on TikTok in 2021–2022 — are that liquid chlorophyll drops clear skin, "detoxify" the blood, "oxygenate" tissues, alkalize body pH, and promote weight loss. This dossier covers the substance and every meaningful consequence the literature surfaces; the entry's job is to separate the real effect (narrow, populations-specific carcinogen binding) from the marketed effect (broad, lifestyle-grade transformation).
Evidence by addressing question
Mechanism
Chlorophyll and chlorophyllin share a planar, electron-dense chlorin macrocycle. The defining reactivity comes from this flat π-system: it forms tight non-covalent stacking ("molecular sandwich") complexes with other flat, ringed molecules. Aflatoxin B1, benzo[a]pyrene, IQ (2-amino-3-methylimidazo[4,5-f]quinoline, a heterocyclic amine from cooked meat), and PhIP are all planar aromatic carcinogens, and all bind chlorophyllin in the gut lumen with high affinity (Dashwood et al. 1996). When the binding happens in the intestine at the time of carcinogen ingestion, the complex is too large and too polar to cross the enterocyte and is excreted in feces. Jubert et al. 2009 demonstrated this directly in humans using AMS-traceable [14C]-aflatoxin B1, showing a roughly 30–40% reduction in systemic AUC when chlorophyllin (or chlorophyll) was co-ingested.
The mechanism is strictly an interceptor mechanism — chlorophyllin binds the toxin in the gut and prevents absorption. It does not "pull toxins out" of stored tissue or "cleanse" liver or blood; once a carcinogen has been absorbed and bound by hepatocyte DNA, chlorophyllin has no documented mechanism to remove it. Co-administration with the dietary carcinogen is required; an evening chlorophyll drink does nothing for a morning's grilled-meat exposure.
Topical chlorophyllin-copper complex (sodium copper chlorophyllin) has a separate mechanistic story. Copper at the porphyrin center is a redox-active metal; the molecule has demonstrated antioxidant capacity in cell-free assays and reduces matrix metalloproteinase (MMP) signaling in fibroblast culture, which is the rationale for photoaged-skin trials. The relevance of cell-culture MMP suppression to clinical photodamage is the usual cosmetic-dermatology gap.
Evidence
Carcinogen binding — the strongest case. Egner et al. 2001 ran the cornerstone trial: a randomized, double-blind, placebo-controlled study of 100 mg chlorophyllin three times daily with meals for 4 months in 180 adults in Qidong, China — a region of historically extreme dietary aflatoxin exposure and hepatocellular-carcinoma incidence ~50× that of the United States. The chlorophyllin arm showed a 55% reduction in urinary aflatoxin-N7-guanine — the DNA adduct biomarker that marks aflatoxin's covalent hit on hepatocyte genome. The reduction was significant from week 2 onward and dose-rhythm consistent with intestinal binding. Jubert et al. 2009 closed the mechanistic loop in healthy U.S. adults: 5 mg of either chlorophyll or chlorophyllin co-ingested with a microdose of [14C]-aflatoxin B1 dropped systemic absorption by roughly a third. Animal data extends the finding to heterocyclic amines from cooked meat and benzo[a]pyrene from charred food and tobacco smoke, with similar dose-dependent interception.
What does not exist: replication of the Qidong adduct-reduction study in a low-aflatoxin Western population, where baseline aflatoxin exposure for most adults is below detection. There is also no completed hard-endpoint trial — hepatocellular-carcinoma incidence, all-cause mortality — for chlorophyllin in any population. The chemoprevention case is biomarker-grounded and mechanistically tight; it has not been carried through to a mortality endpoint.
Skin. Topical chlorophyllin-copper complex has been tested in small manufacturer-supported pilot studies. Stephens et al. 2015 ran an open-label 8-week pilot of 0.1% topical chlorophyllin-copper twice daily in women with facial photodamage, reporting improvements in lines, wrinkles, and skin texture by clinical photography. Sigler and Stephens 2015 ran a similar pilot for mild-to-moderate acne with positive results. Both trials are small (n < 15), open-label, and industry-supported; they generate hypothesis but do not establish efficacy. There are no controlled trials of oral chlorophyll or chlorophyllin for skin outcomes — the most-marketed claim of the TikTok era has zero direct trial support.
Body odor. The "internal deodorant" claim originates in 1940s–50s nursing-home and ostomy-care literature: 100–300 mg/day chlorophyllin was given to reduce fecal and urinary odor in colostomy and incontinence patients, and consistent practitioner reports drove FDA's still-current acceptance of chlorophyllin as a deodorant ingredient in topical and oral products. A controlled trial by Christiansen and Pickrel 1964 in geriatric incontinence patients found no significant effect over placebo on perceived urinary or fecal odor. Small uncontrolled series in trimethylaminuria ("fish-odor syndrome") have shown modest reductions in urinary trimethylamine. For typical adults using liquid chlorophyll for general body odor or breath, no controlled evidence supports the claim.
Wound healing. Chlorophyllin was a routine component of mid-century debriding ointments (PanaFil and similar) for pressure ulcers and slow-healing wounds, on the strength of 1940s Smith and Bowers case series. FDA's 2003 OTC monograph review of skin-protectant products concluded that efficacy of chlorophyllin for wound healing was not established (FDA 2003). Modern wound-care guidelines do not include it. Legacy products persist; they are not evidence-based first-line care.
Protocol
For the one indication with real evidence — intestinal aflatoxin interception in a high-exposure population — the Egner protocol is 100 mg sodium copper chlorophyllin three times daily, taken with meals. The "with meals" qualifier is mechanistic, not casual: the molecule has to be in the gut at the same time the toxin arrives. Taking chlorophyllin between meals or before bed loses most of the effect.
For topical photodamage / acne, the tested formulation is 0.1% chlorophyllin-copper complex cream applied twice daily; trial duration was 8–12 weeks.
For general "skin / detox / energy" use, no protocol has trial backing; liquid drops are typically marketed at 50–100 mg per dose, 1–2× daily.
Contraindications
Chlorophyllin is a designated food-additive color (Citrus Red No. 2 it is not; chlorophyllin is FDA-approved color additive E141 / FD&C-permitted for confectionery and pharmaceuticals) with a benign acute and subchronic safety profile. Reported side effects: green stools and urine (cosmetic, expected), occasional mild GI upset, rare reports of greenish skin staining at very high doses. Theoretical photosensitivity from the porphyrin scaffold is plausible but rarely observed at supplement doses; high-dose oral chlorophyllin in porphyria patients is not recommended. Pregnancy and lactation safety: not formally established; use is not recommended in absence of data. Drug interactions are minimal but in vitro work suggests chlorophyllin can bind some planar aromatic drugs (which would in principle blunt absorption) — clinically demonstrated for none.
Misconceptions
"Chlorophyll is plant blood / oxygenates your blood." Chlorophyll's structure resembles hemoglobin's heme (both porphyrins), but with magnesium replacing iron and a different protein-free environment. Orally ingested chlorophyll is broken down by gastric acid and gut microbes; it does not become hemoglobin, does not carry oxygen, and does not "increase oxygen in the blood." The viral 2021 TikTok claim is biochemically false.
"Detox / cleanse." The carcinogen-binding effect is specific: planar aromatic toxins eaten at the same meal. Chlorophyllin does not remove accumulated toxins from liver, blood, fat tissue, or organs. The detox frame conflates a narrow intestinal-interception mechanism with a magical whole-body purification.
"Alkalizes the body." Blood pH is held between 7.35 and 7.45 by bicarbonate and respiratory buffering. Diet does not move it. The "alkaline" frame is biochemistry as marketing language.
"Clears acne / improves complexion (oral)." Topical chlorophyllin-copper has weak pilot-trial support; oral has none.
"Aids weight loss." One small Swedish study reported reduced appetite with thylakoid extracts (chlorophyll-rich plant membranes, not chlorophyllin). Replication is thin; effect size small. Not a weight-loss intervention.
Practicalities
Forms: liquid drops (sodium copper chlorophyllin, typically 50 mg per dropperful), tablets and capsules (100–200 mg), topical creams (0.1%). Cost: $10–30 per month for oral products in the United States; topical cosmetic products $30–60. Available without prescription, widely stocked. Greens-as-food chlorophyll content: spinach delivers ~150 mg per 100 g cooked, but bioavailability is poor (~25%) and gut breakdown extensive. The "eat the salad, not the drops" intuition is broadly correct for general nutrition; the drops are useful only when chlorophyllin's specific pharmacology is what's wanted.
History
Isolated by Pelletier and Caventou in 1817. Pharmaceutical chlorophyllin (water-soluble copper complex) developed in the 1940s. Smith and Livingston's wound-healing case series and Westcott's deodorant work drove decades of pharmaceutical use. The aflatoxin chemoprevention work began with Bailey, Hendricks, and Dashwood's rainbow-trout models in the 1980s and culminated in the Qidong RCT in 2001. The 2021 TikTok cycle drove the liquid-drops boom and re-introduced 1940s "internal deodorant" claims into a population with no memory of where they came from.
Credibility range
Optimist case. Chlorophyllin's interceptor mechanism is mechanistically tight, structurally specific, and demonstrated in humans by both biomarker reduction (Egner et al. 2001) and direct AMS-tracer pharmacokinetics (Jubert et al. 2009). For populations with measurable dietary aflatoxin exposure — parts of sub-Saharan Africa, South and Southeast Asia, and any region with poorly stored peanuts, corn, or tree nuts — chlorophyllin with meals is one of the cheapest, lowest-risk cancer-prevention interventions documented. The mechanism generalizes credibly to heterocyclic amines from charred meat and PAHs from smoke, both of which are non-trivial Western exposures. Topical chlorophyllin-copper for photodamage and acne has consistent small-trial signal. The substance is cheap, broadly available, low-risk, and FDA-approved as a color additive.
Skeptic case. The Egner adduct-reduction has not been replicated in a low-exposure population, and no hard-endpoint mortality trial exists in any population. The topical skin trials are small (n < 15), open-label, and industry-supported — pilot-tier evidence. The "internal deodorant" use has 1940s precedent but failed its one controlled trial (Christiansen and Pickrel 1964). Oral chlorophyll for skin, detox, blood oxygenation, alkalization, and weight loss has zero controlled-trial support, and several of these claims are biochemically false. The 2021 TikTok cycle drove a buying boom for an effect — clearer skin within days from liquid drops — the literature has never demonstrated. Most Western adults buying chlorophyll drops will get green pee, modest placebo, and a measurable financial transfer to supplement makers.
Author's call. Real but narrow. The carcinogen-binding mechanism is well-established and clinically relevant for high-aflatoxin populations; for typical Western adults, baseline exposure is below the threshold where interception buys much. Topical chlorophyllin-copper has plausible but pilot-tier skin signal. The viral oral-supplement use — clearer skin, body deodorizing, detox, oxygenated blood — is not what the molecule actually does. Eat your greens; if you live in a high-aflatoxin region or eat charred meat daily, chlorophyllin with meals is reasonable; if you're paying $30/month for liquid drops to look better, the math doesn't work. evidence scores 2 (real RCT for one indication, weak elsewhere); controversy scores 2 (mismatch between marketed claims and trial evidence is the operative tension, not within-field disagreement).
Stakeholder and incentive map
- Supplement makers — liquid-drop manufacturers with cosmetic / detox positioning; small, fragmented market boosted enormously by 2021 viral cycle.
- Wound-care manufacturers — legacy debriding-ointment lines (PanaFil and successors) with installed clinical use predating FDA's negative monograph review.
- Cancer-prevention research community — the Linus Pauling Institute, Oregon State, and Johns Hopkins teams who built the interceptor-molecule literature; not commercially incentivized, motivated by population-level liver-cancer reduction in high-exposure regions.
- Cosmetic dermatology research — small manufacturer-supported studies of topical chlorophyllin-copper for photodamage and acne; commercial incentive present.
- Wellness influencers / TikTok — drove the recent buying boom on aesthetic and detox positioning that the science does not support.
- Skeptic counter-incentive — academic dermatologists pushing back on oral chlorophyll for skin; debunkers of the "alkaline" and "oxygenate blood" claims.
Population variability
- High dietary aflatoxin exposure — the population in whom the interceptor mechanism has the largest expected benefit. Defined regions plus anyone consistently consuming poorly stored peanuts, corn, tree nuts.
- Heavy charred-meat eaters — heterocyclic amine / PAH exposure is real; chlorophyllin-with-meals plausibly intercepts, though no human trial exists at this endpoint.
- Smokers, secondhand-smoke exposed — same PAH logic, same evidence gap (rodent data only).
- Typical Western adults — minimal expected benefit from oral chlorophyllin; greens consumption already covers what diet can supply.
- Photodamaged / acne-prone skin — pilot-trial signal for topical chlorophyllin-copper; not first-line, plausible adjunct.
- Ostomy / incontinence patients — historical anecdotal use for fecal/urinary odor; one negative RCT in geriatric populations.
- Pregnancy / lactation — safety not established; avoid.
- Porphyria patients — theoretical phototoxicity concern with porphyrin loading; avoid high doses.
Knowledge gaps
No Western-population RCT of chlorophyllin co-ingestion with charred meat for heterocyclic-amine adduct reduction; the mechanism would predict an effect, but it has not been measured. No long-term hard-endpoint trial — hepatocellular carcinoma incidence, all-cause mortality — for chlorophyllin in any population, despite 25 years since the Qidong biomarker trial. No properly powered RCT of topical chlorophyllin-copper for acne or photodamage outside small industry-supported pilots. No controlled trial of oral chlorophyll for any skin outcome, despite this being the most-marketed claim. No modern controlled re-evaluation of the "internal deodorant" use for incontinence or ostomy populations; the 1964 negative RCT is the most recent rigorous data, in a different patient population than where the 1940s anecdotal reports came from. What would change the author's call: a properly powered Western-population chlorophyllin RCT with adduct or cancer-incidence endpoint; or a controlled trial of oral chlorophyllin for acne or photodamage with clinical (not just photographic) endpoints.
A debunking-shaped entry around a real-but-narrow mechanism. The 2021 viral cycle put a low-impact supplement in front of a much larger audience than its actual indications warrant, so the entry exists mainly to draw the line between the marketed payoffs (skin, body odor, detox, blood oxygen, weight loss) and the one well-evidenced one (intestinal interception of planar aromatic carcinogens, dose-rhythm with meals).
Scope decisions:
- Brief said "skin, body odor, wound healing, carcinogen binding" — article covers all four. Skin and body-odor claims are addressed in evidence (small/failed trials) and misconceptions (the marketed oral form has no support). Wound healing gets a paragraph in evidence (the FDA 2003 negative monograph). Carcinogen binding carries the entry's mechanism and evidence sections. Nothing was silently dropped.
- No
stakesorpayoffsection. A relief-lever debunking entry's stakes and payoff are implicit in misconceptions and failure-modes — adding standalone sections would have padded the entry past its honest weight. - Chlorophyll-rich diet / greens consumption is mentioned in practicalities but not treated as the primary substance. The entry is about the supplement form; the salad case is acknowledged so the reader isn't left with a false binary.
Rating notes:
- longevity = 1 was the contested call. The Egner 2001 trial is genuinely strong evidence for a meaningful effect in a defined population, which would push to 2 or higher on its own. But the entry's substance is the supplement as actually consumed by the catalogue's readership, where baseline aflatoxin exposure is near zero and the predicted effect collapses. A 2 felt overstated for a low-exposure population; 0 erased a real mechanism. 1 with a justification that names the narrow population is the honest call.
- beauty_direct = 1 reflects the topical chlorophyllin-copper pilot signal. The oral form scores 0 in spirit, but the dimension is at the substance level, and topical is the substance. The pitch is explicit that the drops don't do this.
- controversy = 2 captures the marketed-vs-evidenced mismatch rather than within-field disagreement. The aflatoxin literature is consensus; the topical literature is pilot but uncontested.
- applicability = 2 uses the awareness-audience lift: niche supplement use, but the viral cycle made the topic broadly relevant to anyone considering or rejecting the drops.
- action = know rather than
avoidordecide. The honest reading is that for most adults this is a clarity entry — the substance is safe, cheap, and mostly inert at the marketed use; for a narrow population it has a real role. "Know" captures that without painting the substance as something to actively avoid.
Future-link candidates:
- Sulforaphane / cruciferous chemoprevention — same molecular class of question (dietary protection against ingested carcinogens), much larger trial base.
- Heterocyclic amines from charred meat — the exposure side of the chlorophyllin-intercepts mechanism; not yet an entry.
- Aflatoxin and dietary safety — the public-health story that gave chlorophyllin its strongest trial.
- Topical retinoids, benzoyl peroxide, sunscreen — the evidence-based skin trio referenced in out-of-scope.
- "Alkaline diet" — the same debunking pattern with a different substance; one of the misconception lines could be a satellite entry.
Knowledge gap worth flagging for a future re-write: a properly-powered Western RCT of chlorophyllin with adduct or hard-endpoint measurement would move longevity and evidence upward materially. A controlled trial of oral chlorophyll for any skin endpoint would settle the most-marketed claim either way; nothing of the sort is in progress to the author's knowledge.
Chlorophyll and Chlorophyllin
Liquid drops and capsules retail $10–30/month in the US; topical chlorophyllin-copper creams $30–60. Trivial relative to most supplement-aisle interventions.
Drops or capsules with meals; no protocol harder than remembering. The mechanistic with-meals timing is the only friction worth noting.
One well-conducted RCT (Egner 2001) with biomarker endpoint plus one human pharmacokinetic confirmation (Jubert 2009) for the aflatoxin-binding mechanism; small open-label industry pilots for topical skin (Stephens 2015, Sigler 2015); a failed 1964 RCT for the deodorant claim; nothing controlled for the most-marketed oral-skin and detox claims.
Topical chlorophyllin-copper pilot trials (Stephens 2015, Sigler 2015) show mild improvement in photodamage and acne, but trials are small, open-label, and industry-supported. The oral form — the one the TikTok cycle drove — has zero controlled trial support for any skin endpoint.
Egner et al. 2001 (PNAS) showed a 55% reduction in urinary aflatoxin-N7-guanine adducts with 100 mg chlorophyllin three times daily in high-exposure Qidong adults. The mechanism is real and narrow — meaningful for high-aflatoxin or heavily-charred-meat populations, marginal for typical low-exposure adults. No mortality endpoint trial exists.